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outcome by earlier complete revascularization after primary PCI for
STEMI patients with multivessel disease.
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BACKGROUND Activating cardio venous endothelium with a trans-coro-
nary sinus catheter intervention (PICSO) by mechanotransduction and
reversing bloodﬂow in coronary circulation, not only reduces ischemia and
microvascular obstruction, but may also reopen pathways for endogenous
repair. We assessed the hypothesis that a coronary sinus catheter inter-
vention substantiates angiogenesis in an ischemia/reperfusion model.
METHODS 32 open chest pigs received: sham-operation (n¼3); PICSO
normal perfusion (PICSO-A, n¼10); Infarct and reperfusion (control-
group, n¼8), ischemia and reperfusion with PICSO (PICSO-B, n¼11).
LAD was occluded for 3 hours followed by 1 hour reperfusion. Dura-
tion of PICSO was 4 hours in normal hearts and was induced after 30
minutes ischemia continuing through reperfusion (3.5 hours). Spec-
imen were taken from: LAD region (infarct), adjacent zones Border1
and 2, Circumﬂex region remote R, Right ventricle RV. VEGFR1, 2
positive arteries and veins were calculated as percentage of total
number of vessels using confocal-microscopy.
RESULTS VEGFR1was signiﬁcantly upregulated in arteries and veins of
Border1 in PICSO-B, duringnormal bloodﬂow inLAD regions of PICSO-Aand RV in both interventional groups as compared to controls (p<0.05).
VEGFR2 expression in arteries was signiﬁcantly upregulated in Border1
(p<0.001) and Border2 (p<0.05) in PICSO-B as compared to controls and
in arteries of LAD and RV areas of both PICSO groups as compared to
control (p<0.05), whereas no upregulation was found in arteries in R.
Signiﬁcant upregulation could be found in veins in all areas of the PICSO
groups as compared to control and sham-operated animals (p<0.05).
CONCLUSIONS Signiﬁcant upregulation of angiogenesis proteins in
coronary vessels by activation of PICSO in arteries and veins induces
regenerative pathways leading to induction of angiogenesis and
structural repair. The trans-coronary sinus catheter intervention
PICSO induces structural repair besides as a dual mechanism together
with its salvaging effect in acute myocardial injury.
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BACKGROUND The examination study was a multicenter prospective
all-comers randomized controlled trial that compared Everolimus-
eluting stent (EES) versus Bare-metal stent (BMS) in patients with
STEMI. The aim of this study was to compare 1-year clinical outcomes
after EES implantation compared with BMS in patients with diabetes
(DM) included in the EXAMINATION trial.
METHODS Of the 1498 patients included, 258 patients were diabetic
(EES¼137, BMS¼ 121) and 1239 were not (EES¼613, BMS¼626). The
primary endpoint was the patient-oriented combined endpoint
(POCE) and secondary endpoints included the device oriented
endpoint (DOCE) and other clinical parameters. The analysis of the
clinical outcome at 1year was stratiﬁed by backward Cox-regression
models including those variables with a p<0.1 or clinically relevant.
RESULTS Patients with DMpresentedworse baseline clinical characteristics
than non diabetics. At 1 year, POCEwas signiﬁcantly higher in DM compared
with non-DM (20.2%vs. 11.3%; p¼0.001), whereas DOCEwas similar between
groups (9.7% vs. 6.3%; p¼0-6). In the DM subgroup, rates of POCE and DOCE
weresimilarbetweenEESandBMS(19.0%vs.21.5%;p¼0.6and9.5%vs.9.9%;
p¼0.9, respectively). However, in the EES group, the rate of target lesion
revascularization was signiﬁcantly lower compared with that of the BMS
group (2.9%vs. 7.4%;HR: 0.45; 95%CI: 0.24-0.89; p¼0.02). Rates of recurrent
myocardial infarctionanddeﬁnitiveorprobablestent thrombosisweresimilar
between groups (1.5%vs. 4.1%;p¼0.2 and 2.2%vs. 1.7%; p¼0.5, respectively).
CONCLUSIONS At 1 year, EES implantation in diabetics in the setting of
STEMI did not reduce the rate of POCE as compared to BMS. However,
the use of EES was able to reduce the need for repeat revascularization.
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BACKGROUND Experimental studies have supported that platelet
reactivity is associated with hemostatic measurements, vascular
function, and LV remodeling process. The aim of this study was to
compare the inﬂuence of ticagrelor versus clopidogrel on these com-
ponents in STEMI patients.
B108 J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y , V O L . 6 6 , N O . 1 5 , S U P P L B , 2 0 1 5METHODS Weprospectively enrolled STEMI patients undergoing primary
PCI, whom were treated with clopidogrel (600 mg loading and 75 mg QD
maintenance: n ¼ 105) or ticagrelor (180 mg loading and 90 mg bid main-
tenance: n ¼ 64) on top of aspirin. We serially measured platelet reactivity
(usingVerifyNowassay: pre-PCI, post-PCI, and 1-month follow-up), hs-CRP
(pre-PCI, post-PCI, and 1-month follow-up), ﬁbrinogen (pre-PCI and 1-
month follow-up), vascular function (using brachial-ankle pulse wave ve-
locity [baPWV]: post-PCI and 1-month follow-up) and LV remodeling index
(using transthoracic echocardiography: post-PCI and 1-month follow-up).
RESULTS Baseline demographics and laboratorymeasurementswerewell
balanced between the treatments. Compared with clopidogrel treatment,
ticagrelor treatment showed the lower levels of platelet reactivity frompre-
PCI phase (all p values  0.034) (Table). At 1-month follow-up, ticagrelor
treatment sufﬁciently inhibited ADP-induced platelet reactivity (mostly
less than 100 PRU). However, there were no differences in terms with hs-
CRP level, baPWV and LV remodeling index between the treatments.
Interestingly, ticagrelor versus clopidogrel reduced thrombin-mediated
platelet reactivity (224  33 vs. 240  46 BASE; p ¼ 0.030) and enhanced
ﬁbrinogen level (400  104 vs. 360  100 mg/dL; p ¼ 0.027).Variables Clopidogrel Ticagrelor P valueADP-PRPRUpre-PCI 273  64 240  67 0.003PRUpost-PCI 208  78 55  60 < 0.001PRU1-month 169  64 24  37 < 0.001Thrombin-PRBASEpre-PCI 247  56 217  41 0.001BASEpost-PCI 276  52 256  61 0.034BASE1-month 240  46 224  33 0.030Inﬂammation (mg/L) (mg/L)Hs-CRPpre-PCI 7.9  22.2 4.0  9.8 0.193Hs-CRPpost-PCI 40.3  50.7 29.6  47.0 0.251Hs-CRP1-month 4.9  15.9 3.4  5.9 0.505Coagulation (mg/dL) (mg/dL)Fibrinogenpre-PCI 334  100 318  77 0.281Fibrinogen1-month 360  100 400  104 0.027Vascular function (cm/s) (cm/s)baPWVpost-PCI 1620  438 1623  498 0.970baPWV1-month 1479  324 1516  381 0.571LV remodeling index (%) -2.7  27.3 -6.0  23.8 0.609CONCLUSIONS After the short-term treatment with ticagrelor versus
clopidogrel, its strong inhibition of platelet activation is not associ-
ated with inﬂammation, vascular function and LV remodeling process
in STEMI patients. Beneﬁcial role of ticagrelor needs to be evaluated
in randomized clinical trials after long-term treatment.
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BACKGROUND Successful percutaneous coronary intervention (PCI)
of the occluded infarct-related artery (IRA) in latecomers may improve
long-term survival mainly by reducing left ventricular remodeling. It is
not clear whether inhibition of renin-angiotensin system (RAS) brings
additional better clinical outcomes in this speciﬁc population subset.
METHODS Between January 2008 and June 2013, 669 latecomer pa-
tients with acute myocardial infarction (MI) (66.2  12.1 years old,
71.0% males) in Korea Acute Myocardial Infarction Registry (KAMIR)who underwent a successful PCI were enrolled. The study population
underwent a successful PCI for a totally occluded IRA. They were
divided into two groups according to whether they were prescribed
RAS inhibitors at the time of discharge or not: group I (RAS inhibition,
n¼556), and group II (No RAS inhibition, n¼113).
RESULTS During the one-year follow-up, major adverse cardiac
events (MACE), which consist of cardiac death and MI, occurred in 71
patients (10.6%). There were signiﬁcantly reduced incidences of
MACE in the group I [hazard ratio (HR) ¼ 0.34, 95% CI (conﬁdence
interval) 0.199 - 0.588, p¼0.001]. In subgroup analyses, RAS inhibition
was beneﬁcial in patients with male gender, history of hypertension
or diabetes mellitus, and even in patients with left ventricular ejection
fraction (LVEF) 40%. In the baseline and follow-up echocardio-
graphic data, beneﬁt in changes of LVEF and left ventricular end-
systolic volume was noted in the group I.
Comparison between baseline and follow-up echocardiographic data.VariableGroup I
(RAS inhibition,
n[556)Group II
(no RAS inhibition,
n[113) p valueBaselineLVEF (%) 51.9  10.6 51.3  14.1 0.595LVESV (ml) 57.5  17.6 58.2  21.8 0.678LVEDV (ml) 118.9  19.7 118.6  18.9 0.889Follow-upTime interval from
baseline exam
(days)117  58.3 121  62.5 0.328LVEF (%) 55.6  11.1 50.7  11.9 <0.001LVESV (ml) 51.6  17.8 59.3  21.2 <0.001LVEDV (ml) 115.1  18.3 118.9  19.2 0.048% change from the baseline
examLVEF (%) 9.4  24.9 2.6  23.0 0.007LVESV (ml) -7.5  28.3 7.2  32.3 <0.001LVEDV (ml) -1.3  19.3 2.4  22.8 0.071CONCLUSIONS In latecomers with acute MI, RAS inhibition improved
long-term clinical outcomes after a successful PCI, even in patients
with low risk who had relatively preserved LVEF.
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